Evidence map›Paper›PMID 40965656›Full record

SynthesisNaunyn-Schmiedeberg's archives of pharmacology2026

Which antiplatelet is better after stents? A meta-analysis of aspirin vs clopidogrel in the maintenance phase.

Omar Almaadawy, Mohamed Elnady, Hossam Elbenawi, Ahmed Almahdy Mohamed, Abdelrahman Elshimy, Menna Sarhan, Abdul Rhman Hassan, Eman Moheyeldin, Alshaimaa G Mohamed, Nada Ali and 5 more

Abstract readMeta-AnalysisSystematic ReviewComparative Study
PubMed Publisher
In one paragraph

Synthesis in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Omar Almaadawy *Department of Internal Medicine, MedStar Health, Baltimore, MD, 21218, USA. omaadawy@gmail.com.
Mohamed Elnady *Faculty of Medicine, Kafr El Sheikh University, Kafr El Sheikh, Egypt.
Hossam ElbenawiDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, USA.
Ahmed Almahdy MohamedDepartment of Medicine, Division of Cardiology, University of Minnesota Twin Cities, Minneapolis, MN, USA.
Abdelrahman ElshimyFaculty of Medicine, Alexandria University, Alexandria, Egypt.
Menna SarhanFaculty of Medicine, Zagazig University, Sharkia, Egypt.
Abdul Rhman HassanFaculty of Medicine, Tanta University, Tanta, Egypt.
Eman MoheyeldinFaculty of Medicine, Menofia University, Menofia, Egypt.
Alshaimaa G MohamedFaculty of Medicine, Fayoum University, Fayoum, Egypt.
Nada AliFaculty of Pharmacy, Egyptian Russian University, Badr, Egypt.
Muhammad EltonyDepartment of Internal Medicine, MedStar Health, Baltimore, MD, 21218, USA.
Abdalla ElmansouryFaculty of Medicine, Alexandria University, Alexandria, Egypt.
Claudia GeorgesDepartment of Internal Medicine, MedStar Health, Baltimore, MD, 21218, USA.
Youmna ElsalmounyFaculty of Medicine, Port Said University, Port Said, Egypt.
Karim Al-AziziDepartment of Interventional and Structural Cardiology, Baylor Scott and White The Heart Hospital, Plano, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronary artery disease (CAD) remains a leading cause of global mortality and disability, with percutaneous coronary intervention (PCI) being a prevalent treatment. Dual antiplatelet therapy (DAPT) followed by single antiplatelet therapy (SAPT) is a standard approach post-PCI. However, the optimal choice between aspirin and clopidogrel during SAPT, especially for high risk of bleeding patients, remains debated. This systematic review and meta-analysis aimed to assess the effectiveness and safety of aspirin versus clopidogrel monotherapy in CAD patients after PCI. A comprehensive literature search identified 11 studies (seven RCTs and four cohorts) involving 26,324 patients, with 11,435 on clopidogrel and 14,889 on aspirin. Our analysis found that clopidogrel was significantly associated with no significant difference regarding major bleeding compared to aspirin; however, after sensitivity analysis, clopidogrel monotherapy resulted in statistically significant 36% and 25% reduction, respectively. The findings suggest that clopidogrel monotherapy is not inferior to aspirin monotherapy, warranting its consideration in long-term SAPT post-PCI.

Indexed as

AspirinClopidogrelCoronary Artery DiseasePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsStentsHemorrhageHumansTreatment OutcomeAspirinClopidogrelPlatelet Aggregation InhibitorsAntiplatelet therapyBleeding riskCoronary artery diseaseMeta-analysisMyocardial infarctionPercutaneous coronary interventionStroke

Identifiers

PMID40965656

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.